Tridiuum and NOCD Partner to Diagnose OCD Patients Faster and Accelerate Access to Clinically Proven Treatment

Tridiuum and NOCD Partner to Diagnose OCD Patients Faster and Accelerate Access to Clinically Proven Treatment
Integration of solutions from top behavioral health company and leading specialty provider will facilitate rapid, data-driven referrals and empower patients to receive the right treatment in less time
News provided by
Share this article
Tridiuum, the nation's premier provider of digital behavioral health solutions, and
NOCD, the leading provider for the treatment of obsessive-compulsive disorder (OCD), today announced a first-of-its kind partnership to support individuals suffering from OCD.  The new partnership focuses on identifying more patients with OCD to diagnose them correctly faster and with less effort. The integrated approach will guide patients to NOCD's therapy, which is clinically proven to reduce impairment and distress from OCD symptoms in 90 percent of patients.

Related Keywords

Philadelphia , Pennsylvania , United States , Mark Redlus , Stephen Smith , Lisa Chernikoff , Centers For Disease , Canton Company For Tridiuum , Disease Control , Exposure Response Prevention , Response Prevention , Tridiuum , பிலடெல்பியா , பென்சில்வேனியா , ஒன்றுபட்டது மாநிலங்களில் , ஸ்டீபன் ஸ்மித் , மையங்கள் க்கு நோய் , நோய் கட்டுப்பாடு , நேரிடுவது பதில் ப்ரெவெந்ஶந் , பதில் ப்ரெவெந்ஶந் ,